Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip R Greipp

Showing results (21-30 of 113) with videos related to

Pageof 12
Sort By:
Cancer|February 28, 2009
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93Robert A Kyle, Susanna Jacobus, William R Friedenberg, et al.
Human Gene Therapy|October 1, 2009
Infection and killing of multiple myeloma by adenovirusesJulien S Senac, Konstantin Doronin, Stephen J Russell, et al.
Cancer|October 20, 2004
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyIrene M Ghobrial, Rafael Fonseca, Philip R Greipp, et al.
Haematologica|July 22, 2008
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosisMorie A Gertz, Martha Q Lacy, John A Lust, et al.
Cancer|March 28, 2006
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantationRobert A Kyle, Traci Leong, Shuli Li, et al.
Blood|May 8, 2004
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionShaji Kumar, Thomas E Witzig, Michael Timm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Clinical impact of discordance in serum albumin measurements on myeloma international staging systemPrashant Kapoor, Christine L H Snozek, Colin Colby, et al.
Experimental Hematology|May 27, 2006
Oncolytic measles virus targets high CD46 expression on multiple myeloma cellsHooi Tin Ong, Michael M Timm, Philip R Greipp, et al.
Cancer|January 19, 2006
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology GroupWilliam R Friedenberg, Montserrat Rue, Emily A Blood, et al.
Clinical Chemistry|April 28, 2007
Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myelomaChristine L H Snozek, Amy K Saenger, Philip R Greipp, et al.
Pageof 12

Showing results (21-30 of 113) with videos related to

Sort By:
Pageof 12
Cancer|February 28, 2009
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93Robert A Kyle, Susanna Jacobus, William R Friedenberg, et al.
Human Gene Therapy|October 1, 2009
Infection and killing of multiple myeloma by adenovirusesJulien S Senac, Konstantin Doronin, Stephen J Russell, et al.
Cancer|October 20, 2004
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyIrene M Ghobrial, Rafael Fonseca, Philip R Greipp, et al.
Haematologica|July 22, 2008
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosisMorie A Gertz, Martha Q Lacy, John A Lust, et al.
Cancer|March 28, 2006
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantationRobert A Kyle, Traci Leong, Shuli Li, et al.
Blood|May 8, 2004
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionShaji Kumar, Thomas E Witzig, Michael Timm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Clinical impact of discordance in serum albumin measurements on myeloma international staging systemPrashant Kapoor, Christine L H Snozek, Colin Colby, et al.
Experimental Hematology|May 27, 2006
Oncolytic measles virus targets high CD46 expression on multiple myeloma cellsHooi Tin Ong, Michael M Timm, Philip R Greipp, et al.
Cancer|January 19, 2006
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology GroupWilliam R Friedenberg, Montserrat Rue, Emily A Blood, et al.
Clinical Chemistry|April 28, 2007
Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myelomaChristine L H Snozek, Amy K Saenger, Philip R Greipp, et al.
Pageof 12